DPT

Discovery

DPT was first synthesized in the early 1950s as part of a systematic campaign to characterize N,N-dialkyl tryptamine analogs.^[3] Animal testing confirmed pharmacological activity in 1954,^[8] and human psychedelic properties were established during the 1960s.^[9] DPT was encountered as a novel designer drug as early as 1968.

Clinical research

The only controlled clinical studies of DPT were conducted at the Maryland Psychiatric Research Center between 1973 and 1980 by a team including Stanislav Grof, Richard Soskin, and William Richards. A study of 103 male alcoholic patients used low-dose sessions (15–45 mg) for therapeutic preparation followed by a single high-dose session (75–265 mg), with therapist-rated improvements in emotional expressiveness and self-exploration.^[4] A later pilot project administered DPT (75–227.5 mg) to 30 cancer patients experiencing psychological distress, targeting "peak experiences" as a therapeutic endpoint.^[5] No clinical trials have been conducted since.

Regulatory history and modern re-emergence

DPT remains federally unscheduled in the United States as of 2026. The DEA proposed scheduling several tryptamines in January 2022 but withdrew the proposal that July. DPT has reappeared on research chemical markets as a novel psychoactive substance; the Centre for Forensic Science Research and Education first identified it in forensic casework in March 2025.^[6]

Structure

N,N-Dipropyltryptamine belongs to the substituted tryptamine family, sharing the indole-ethylamine backbone common to DMT, psilocin, and endogenous serotonin. DPT differs from DMT solely at the amine nitrogen: two n-propyl groups replace DMT's two methyl groups.

This increased bulk at the nitrogen reduces susceptibility to monoamine oxidase breakdown and increases lipophilicity,^[11] which is why DPT is orally active without an MAO inhibitor — a key distinction from DMT. DPT contains no stereocenters and is achiral.^[8]

Physical properties

The hydrochloride salt forms a white crystalline solid with a melting point of 178–179°C.^[12] The free base exists as an oily liquid at room temperature.^[6] No published data characterize solubility, degradation pathways, or long-term stability.

DPT is purely synthetic and has not been found to occur naturally in humans or other organisms.^[8]

Structure-activity relationships

The N,N-dipropyl substitution is DPT's defining structural feature. Lengthening DMT's methyl chains to propyl chains substantially increases the molecule's resistance to MAO-mediated deamination, enabling oral bioavailability without enzyme inhibition. The longer chains also raise lipophilicity (XLogP 4.3 vs. ~2.0 for DMT),^[11] suggesting efficient passage across the blood-brain barrier. These two changes — metabolic resistance and lipophilicity — account for DPT's longer duration and oral activity compared to DMT.

Mechanism of action

DPT produces its psychedelic effects primarily through activation of the 5-HT₂A serotonin receptor.^[1] This has been confirmed across multiple species: the selective 5-HT₂A blocker MDL100907 completely abolishes DPT's behavioral effects in mice, rats, and primates.^[13][14][15]

DPT also partially activates the 5-HT₁A serotonin receptor.^[1] This secondary action is normally overshadowed by the dominant 5-HT₂A effects but becomes apparent when 5-HT₂A is pharmacologically blocked.^[14]

What sets DPT apart from other classical psychedelics is its action at the SERT (SERT). DPT enters serotonin neurons through this transporter and displaces stored serotonin into the synapse^[2] — a mechanism more typically associated with MDMA than with psychedelics like DMT. This dual action — direct receptor activation plus transporter-mediated serotonin release — places DPT pharmacologically between the purely receptor-driven psychedelics and the predominantly releaser-driven empathogens.^[16]

DPT also enters intracellular vesicles via the vesicular monoamine transporter (VMAT2).^[2] An unidentified anticonvulsant mechanism — independent of serotonin receptors and sigma-1 receptors — has been observed at lower doses in animal models.^[1]

Pharmacokinetics

No human pharmacokinetic studies have been published for DPT. Bioavailability, plasma half-life, and specific metabolic pathways remain uncharacterized.

Oral doses of 100–250 mg produce psychedelic effects,^[12] compared with intramuscular doses of roughly 15–60 mg used in clinical studies,^[4][5] implying substantial first-pass metabolism by the liver. DPT is presumed to undergo deamination by MAO-A and N-dealkylation of its propyl chains, but no CYP enzyme data exist.

DPT is moderately lipophilic,^[11] suggesting efficient brain penetration. Oral effects last 2–4 hours; smoked effects persist roughly 20 minutes; insufflated effects last 3–5 hours.^[12] The oral duration is intermediate between smoked DMT and oral psilocybin.

Where it acts

No direct neuroimaging or electrophysiology studies of DPT have been published. Based on its confirmed 5-HT₂A agonism, DPT is expected to act on deep-layer pyramidal neurons in the prefrontal cortex, disrupting the brain's default filtering of sensory and cognitive input — particularly the default mode network.

DPT's concurrent serotonin release through the SERT^[2] adds a neurochemical dimension absent in purely receptor-driven psychedelics like DMT. This flood of synaptic serotonin may contribute to the empathogenic qualities — enhanced emotional expressiveness and deepened interpersonal connection — consistently documented in clinical settings.^[4]

Why it matters

The relaxed beliefs under psychedelics (REBUS) model predicts that DPT's 5-HT₂A agonism would temporarily loosen the brain's prior expectations, allowing bottom-up sensory and emotional information to surface more freely. The clinical reports of profound self-exploration and "peak experiences"^[5] fit this framework.

DPT's 5-HT₂A activation also predicts neuroplasticity-promoting effects through BDNF and related signaling pathways, but no direct neuroplasticity assays have been published for DPT.

Toxicity

No lethal dose has been established for DPT in any species. No therapeutic index can be calculated, and the threshold for toxic effects in humans is unknown.

Psychological risks

Acute psychological distress is a predictable risk, consistent with all serotonergic psychedelics. Clinical studies reported low rates of serious psychological adverse effects in supervised settings,^[4][5] but specific adverse event rates are unavailable.

Anxiety has been documented in DPT effects profiles.^[6] Precipitation of psychotic episodes in individuals with personal or family history of psychotic disorders is a class-level risk.safety citation needed No DPT-specific data on HPPD (HPPD) exist; class-level risk is acknowledged.^[6]

Tolerance & dependence

DPT does not produce tolerance to its own effects in mice, contrasting sharply with phenethylamine psychedelics which rapidly develop tolerance.^[17] Cross-tolerance from phenethylamine psychedelics to DPT does occur — animals tolerant to DOI show reduced response to DPT — but the reverse was not tested.^[17]

DPT is not considered habit-forming, consistent with the psychedelic class as a whole.^[13] No dependence, self-administration, or withdrawal data have been published.

Drug interactions

DPT's dual serotonergic mechanism — direct receptor activation combined with serotonin release through the transporter — creates compounded risk with any drug that raises synaptic serotonin.

MAO inhibitors are the most dangerous predicted combination. DPT releases serotonin into the synapse; monoamine oxidase inhibition prevents that serotonin from being broken down, producing sustained toxic concentrations. Life-threatening serotonin syndrome is the expected outcome.safety citation needed

SSRIs, SNRIs, and tricyclic antidepressants add further serotonergic load through reuptake inhibitor, elevating serotonin syndrome risk when combined with DPT's dual mechanism.safety citation needed

Other 5-HT₂A agonists produce additive effects with DPT in animal models.^[18] Drugs that block 5-HT₁A receptors may intensify DPT's hallucinogenic effects, while 5-HT₁A agonists may dampen them.^[13]

No data exist on CYP enzyme interactions, making pharmacokinetic interaction prediction impossible.

Contraindications

Seizure disorders are contraindicated based on substance-specific evidence: DPT is proconvulsant at high doses in animals^[1] and the single fatal case involved seizure.^[7]

Concurrent MAO inhibitor use is an absolute contraindication. The combination of serotonin release and direct receptor activation creates clear pharmacological grounds for life-threatening serotonin syndrome.safety citation needed

Personal or family history of psychotic disorders or bipolar disorder is a standard class contraindication given 5-HT₂A agonism.safety citation needed

Heart conditions including uncontrolled high blood pressure are contraindicated based on expected serotonergic cardiovascular stimulation.safety citation needed

Pregnancy and breastfeeding — no safety data exist.

DPT occupies an unusual regulatory position: it remains federally unscheduled in the United States and Canada, while being controlled in the United Kingdom, several EU member states, Japan, and New Zealand. The Federal Analogue Act (21 U.S.C. §813) may apply to DPT in the United States if intended for human consumption, given its structural relationship to scheduled tryptamines. Two U.S. states have independently scheduled DPT.

Analog act considerations

In the United States, DPT's structural relationship to DMT (Schedule I) makes it potentially subject to the Federal Analogue Act, which treats substances "substantially similar" to Schedule I/II compounds as equivalent when intended for human consumption. DPT differs from DMT only in N-alkyl chain length, which would likely satisfy the structural similarity criterion.^[19]